Multi-institutional study finds that enrollment and outcomes were similar across racial and ethnic groups for children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.
Unique molecular “fingerprints” could explain the disparity in Wilms tumor incidence and point to novel, race-specific therapeutic targets.
Accessibility Tools